Effects of polymorphism of the β1 adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol

Journal of International Medical Research

Volumn 36, Issue 6, 2008, Pages 1354-1362

  Yuan, Hong ^a   Huang, Z ^a   Yang, G ^a   Lv, H ^a   Sang, H ^a   Yao, Y ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CYP2D6; Gene polymorphism; Hypertension; Metoprolol; 1 Adrenergic receptor

Indexed keywords

ARGININE; BETA 1 ADRENERGIC RECEPTOR; CYTOCHROME P450 2D6; METOPROLOL; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; CHINESE HAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG METABOLISM; ESSENTIAL HYPERTENSION; ETHNIC GROUP; GENETIC POLYMORPHISM; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PREDICTION; PROTEIN POLYMORPHISM; RECOMMENDED DRUG DOSE; SYSTOLIC BLOOD PRESSURE; ADOLESCENT; BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; GENETIC PREDISPOSITION; GENETICS; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC PREDISPOSITION TO DISEASE; HEART RATE; HUMANS; HYPERTENSION; METOPROLOL; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, BETA-1; YOUNG ADULT;

EID: 59649106561     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600624     Document Type: Article

References (30)

1. Cowley AW Jr: The genetic dissection of essential hypertension Nat Rev Genet 2006: 7: 829-840.
2. Lalouel JM: Large-scale search for genes predisposing to essential hypertension, Am J Hypertens 2003; 16: 163-166
3. Lee WK, Padmanabhan S, Dominiczak AF: Genetics of hypertension: from experimental models to clinical applicaiton. J Hum Hypertens 2000; 14: 631-647.
4. Lifton RP, Jeunemaitre X: Finding genes that cause human hypertension. J Hypertens 1993; 11: 231-236.
5. Fux R, Mörike K, Pröhmer Am, et al: Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol a prospective clinical study. Clin Pharmacol Ther 2005; 78: 378-387.
6. Lennard MS, Silas JH, Freestone S, et al: Oxidation metabolism and response. N Engl J Med 1982, 307: 1558-1560.
7. McGourty JC, Silas JH, Lennard MS, et al: Metoprolol metabolism and debrisoquine oxidation polymorphism - population and family studies. Br J Clin Pharmacol 1985; 20: 555-566.
8. Lennard MS, Tucker GT, Woods HF: The polymorphic oxidation of beta adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1986; 11: 1-17.
9. Zanger UM, Fischer J, Raimundo S, et al: Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001; 11: 573-585.
10. Zanger UM, Raimundo S, Eichelbaum M: Cytochrome P450 2D6 overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004, 269: 23-37.
11. Freestone S, Silos JH, Lennard MS, et al: Comparison of two long-acting preparations of metoprolol with conventional meloprolol and atenololin healthy men during chronic dosing Br J Clin Pharmacol 1982; 14: 713-718.
12. Ablad B, Carlsson B, Carission E, et al: Cardiac effects of beta-adrenergic receptor antagonists. Adv Cardiol 1974; 12: 290-302.
13. Insel PA, Snavely MD: Catecholamines and the kidney: receptors and renal function. Annu Rev Physiol 1981; 43 625-636.
14. Faln JN, García-Sáinz JA: Adrenergic regulation of adipocyte metabolism. J Lipid Res 1983; 24: 945-966.
15. 1-adrenoceptor. Br J Clin Pharmacol 2005; 60: 235-243.
16. Kevision Committee of the Chinese Guidelines of Prevention and Treatment of Hypertension 2004 Chines guidelines on prevention and treatment of hypertension. Chin J Hypertens 2004; 12: 483-486 [in Chinese]
17. 1 adrenergic receptor. J Biol Chem 1999; 274: 12670-12674.
18. Taguchi M, Nozawa T, Kameyama T, et al: Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. Eur J Clin Pharmacol 2003, 59: 385-388.
19. Liggett SB: Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology 2000; 61: 167-173.
20. Kirchheiner J, Heesch C, Bauer S, et al: Impact of the ultrarapic metabolizer genotype of cytochrome P45 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2004; 76: 302-312.
21. Liun GZ, Hu DY, Tao P, et al: Suggestions of evaluation method on clinical trial of cardiovascular medicines. Zhonghua Xin Xue Guan Bing Zu Zhi 1998; 26: 5-11.
22. Motulsky AG: Drug reactions enzymes, and biochemical genetic. J Am Med Assoc 1957; 165: 835-837.
23. Turner ST, Schwartz GI, Chapman AB, et al: Antihypertensive pharmacogenetics: getting the right drug into the right patients. J Hypertens 2001; 19: 1-11.
24. Sookolon S, Gianotti TF, Gonzalez CD, et al: Association of the C-344T aldosterone synthase gene variant with essential hypertension a meta-analysis. J Hypertens 2007; 25: 5-13.
25. Regardh CG, Johnsson G: Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet 1980; 5: 557-569.
26. 1 adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003; 74: 372-379.
27. 1 adrenergic receptor gene and hyoertension. Circulation 2001; 104: 187-190.
28. 1- Adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74: 44-52.
29. Zineh I, Beitelshees AL, Gaedigk A, et al: Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficary in hypertension. Clin Pharmacol Ther 2004; 76: 536-544.
30. Liu ZQ, Zhou HH: New era of individualized pharmacotherapy. Chin J Clin Pharmacol Ther 2007; 12: 1-6.